The upregulation of Osteopontin mediates acquired resistance to EGFR-TKI in NSCLC through Integrin/FAK signaling

被引：0
|
作者：
Fu, Yulong [1 ]
Zhang, Yang [1 ]
Liu, Zeyi [1 ]
Huang, Jian-An [1 ]
机构：
[1] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
来源：
EUROPEAN RESPIRATORY JOURNAL | 2020年 / 56卷
关键词：
Lung cancer; Treatments;
D O I：
10.1183/13993003.congress-2020.1762
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
1762
引用
收藏
页数：2
相关论文
共 31 条
  • [1] In vitro study on blocking mTOR signaling pathway in EGFR-TKI resistance NSCLC
    Xiang, Xu-Dong
    Yu, Jing
    Li, Gao-Feng
    Xie, Lin
    Li, Heng
    ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2014, 7 (05) : 394 - 397
  • [2] MYC expression and fatty acid oxidation in EGFR-TKI acquired resistance
    Wang, GuoSheng
    Li, Tao
    Wan, Yuan
    Li, Qiang
    DRUG RESISTANCE UPDATES, 2024, 72
  • [3] Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance
    Lee, Jeong Eun
    Park, Hee Sun
    Lee, Dahye
    Yoo, Geon
    Kim, Tackhoon
    Jeon, Haeyon
    Yeo, Min-Kyung
    Lee, Choong-Sik
    Moon, Jae Young
    Jung, Sung Soo
    Kim, Ju Ock
    Kim, Sun Young
    Park, Dong Il
    Park, Yeon Hee
    Lee, Jae Cheol
    Oh, In-Jae
    Lim, Dae Sik
    Chung, Chaeuk
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 474 (01) : 154 - 160
  • [4] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wang, Wenxian
    Wang, Hong
    Lu, Peihua
    Yu, Zongyang
    Xu, Chunwei
    Zhuang, Wu
    Song, Zhengbo
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (1)
  • [5] RNA Structural Dynamics Modulate EGFR-TKI Resistance Through Controlling YRDC Translation in NSCLC Cells
    Shi, Boyang
    An, Ke
    Wang, Yueqin
    Fei, Yuhan
    Guo, Caixia
    Zhang, Qiangfeng Cliff
    Yang, Yun-Gui
    Tian, Xin
    Kan, Quancheng
    GENOMICS PROTEOMICS & BIOINFORMATICS, 2023, 21 (04) : 850 - 865
  • [6] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wenxian Wang
    Hong Wang
    Peihua Lu
    Zongyang Yu
    Chunwei Xu
    Wu Zhuang
    Zhengbo Song
    Journal of Translational Medicine, 17
  • [7] Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma
    Uramoto, Hidetaka
    Shimokawa, Hidehiko
    Hanagiri, Takeshi
    Kuwano, Michihiko
    Ono, Mayumi
    LUNG CANCER, 2011, 73 (03) : 361 - 365
  • [8] Identification of expression profiles and transcription factors during EGFR-TKI acquired resistance in LUAD
    Feng, Lili
    Wang, Cenzhu
    Chen, Jiawen
    Tao, Chenyue
    Zhang, Liuliu
    Zhou, Luojing
    PRECISION MEDICAL SCIENCES, 2024, 13 (04): : 221 - 231
  • [9] Triple Trouble: A Case of Multiple Resistance Mechanisms after First Generation EGFR-TKI in NSCLC
    Ralki, Mike
    Maes, Brigitte
    Pat, Karin
    Wynants, Jokke
    Cuppens, Kristof
    CASE REPORTS IN ONCOLOGY, 2019, 12 (02): : 625 - 630
  • [10] Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC
    Kim, Dong Min
    Kim, Mi Jin
    Moon, Jai-Hee
    Lee, Eun Young
    Hong, Jun Ki
    Lee, Seul
    Koh, Dong-In
    Ryu, Yae Seong
    Kim, Seung Mi
    Jung, Soo-A
    Shin, Jae-Sik
    Kim, Joseph
    Park, Yoon Sun
    Hong, Seung-Woo
    Lee, So Hee
    Jung, Joonyee
    Park, Sang Soo
    Kim, Do Yeon
    Kim, Eun Ho
    Jeong, Hong-Rae
    Gong, Ji Hee
    Kim, Jieun
    Kim, Seung Chan
    Yu, Ha Na
    Ki, So Young
    Kim, Tae Won
    Jin, Dong-Hoon
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 527 (01) : 305 - 310
1234